A significant proportion of cancers (5%, Figure 1) across the majority of tumor subtypes (Figure 2) harbor MUTs and/or CNVs of this gene involved in the pathogenesis of PD; however, the role of LRRK2 in cancer development remains to be elucidated, and the possible driver or passenger role of LRRK2 alterations in cancer needs yet to be established. This evidence concerns the gene LRRK2 and neoplasm.